Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Rhea-AI Summary

Ocugen (NASDAQ: OCGN) will host a live webcast and conference call at 8:00 a.m. EDT on Tuesday, March 24, 2026 to discuss full Phase 2 ArMaDa clinical trial data for OCU410, a modifier gene therapy for geographic atrophy (late-stage dry AMD).

Key opinion leaders and Ocugen executives will present; a replay and archived webcast will be available on the company investor site. Dial-in and webcast details provided for attendees.

News Market Reaction – OCGN

+2.94%

19 alerts

+2.94% News Effect

+7.5% Peak Tracked

-21.1% Trough Tracked

+$21M Valuation Impact

$750.88M Market Cap

0.1x Rel. Volume

On the day this news was published, OCGN gained 2.94%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.5% during that session. Argus tracked a trough of -21.1% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $21M to the company's valuation, bringing the market cap to $750.88M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Webcast time: 8 a.m. EDT Webcast date: March 24, 2026 US dial-in: (800) 715-9871 +2 more

5 metrics

Webcast time 8 a.m. EDT Scheduled OCU410 Phase 2 data webcast on March 24, 2026

Webcast date March 24, 2026 Conference call and webcast to discuss full Phase 2 ArMaDa dataset

US dial-in (800) 715-9871 U.S. access number for Ocugen OCU410 Phase 2 data call

International dial-in (646) 307-1963 International access number for OCU410 webcast

Conference ID 4629682 Conference identifier for March 24, 2026 OCU410 webcast

Market Reality Check

Price: $1.9600 Vol: Volume 24,467,281 is 2.04...

high vol

$1.9600 Last Close

Volume Volume 24,467,281 is 2.04x the 20-day average of 11,975,901, indicating elevated trading ahead of the webcast. high

Technical Shares at $2.04 are trading above the 200-day MA of $1.37, despite a -8.93% 24h decline.

Peers on Argus

OCGN fell 8.93% while key biotech peers showed mixed single-day moves (e.g., FDM...

OCGN fell 8.93% while key biotech peers showed mixed single-day moves (e.g., FDMT -0.23%, MBX +0.88%, BNTC -4.44%), and no peers appeared in the momentum scanner, pointing to a stock-specific move.

Previous Clinical trial Reports

5 past events · Latest: Mar 02 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 02	Phase 3 enrollment	Positive	+6.6%	Completion of 140‑patient Phase 3 liMeliGhT enrollment for OCU400.
Jan 15	Phase 2 data	Positive	-13.8%	Positive preliminary 12‑month Phase 2 OCU410 data in geographic atrophy.
Jan 13	Data webcast	Positive	+7.3%	Announcement of webcast to review OCU410 Phase 2 ArMaDa clinical data.
Jan 12	Phase 1 results	Positive	+18.7%	Publication of Phase 1 GARDian1 OCU410ST data with efficacy and safety.
Jul 18	Pivotal trial start	Positive	+2.0%	First patient dosed in Phase 2/3 GARDian3 pivotal trial for OCU410ST.

Pattern Detected

Clinical trial headlines for Ocugen have usually been followed by positive price reactions, with only one notable negative move despite positive OCU410 data.

Recent Company History

Over the past year, Ocugen’s clinical‑trial updates have centered on its modifier gene therapy pipeline, including OCU400, OCU410, and OCU410ST. Key events include completion of Phase 3 liMeliGhT enrollment for OCU400 on 2026-03-02 and multiple data readouts and milestones for OCU410 and OCU410ST, often paired with webcast events for KOL discussion. These clinical catalysts frequently produced positive single‑day moves, framing the new OCU410 Phase 2 webcast as part of a continuing data‑driven narrative in retinal diseases.

Historical Comparison

+4.2% avg move · Past clinical‑trial headlines for Ocugen moved the stock an average of 4.15%. Prior OCU410 webcasts ...

clinical trial

+4.2%

Average Historical Move clinical trial

Past clinical‑trial headlines for Ocugen moved the stock an average of 4.15%. Prior OCU410 webcasts and data updates showed mixed but generally positive reactions around similar retinal gene‑therapy milestones.

Clinical news shows progression from early OCU410ST and OCU410 data to pivotal GARDian3 enrollment and Phase 3 liMeliGhT enrollment for OCU400, with repeated webcast events to discuss emerging retinal gene‑therapy results.

Market Pulse Summary

This announcement schedules a KOL‑led webcast to review the full Phase 2 ArMaDa dataset for OCU410 i...

Analysis

This announcement schedules a KOL‑led webcast to review the full Phase 2 ArMaDa dataset for OCU410 in geographic atrophy, highlighting Ocugen’s continued focus on retinal gene therapies. Historically, similar clinical‑trial and data‑discussion events have been important catalysts for the stock. Investors may watch for detailed efficacy and safety metrics, how results compare with earlier OCU410 readouts, and any guidance on Phase 3 timelines and regulatory strategy to gauge the program’s longer‑term significance.

Key Terms

phase 2, clinical trial, modifier gene therapy, geographic atrophy, +1 more

5 terms

phase 2 medical

"full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

clinical trial medical

"Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

modifier gene therapy medical

"OCU410—Modifier Gene Therapy for Geographic Atrophy"

Modifier gene therapy is a treatment that changes the activity of genes that influence how severe or how a disease progresses, rather than directly fixing the original faulty gene. Think of it as turning a volume knob on disease symptoms: it can make conditions milder or slow progression, which matters to investors because it can expand the number of patients who benefit, affect how quickly and cheaply a product can reach the market, and change commercial and regulatory risk and reward.

geographic atrophy medical

"evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related"

Geographic atrophy is a progressive eye condition in which patches of light-sensing cells in the retina die, causing growing blind spots and ultimately significant central vision loss. For investors, it matters because the condition defines the market size and urgency for drugs, devices, and diagnostics — like a spreading hole in a photograph that companies aim to stop or repair — so clinical results, approvals, and reimbursement determine potential revenue and risk.

age-related macular degeneration medical

"late-stage dry age-related macular degeneration (dAMD) at 8 a.m."

Age-related macular degeneration is an eye condition in older adults where the central part of the retina (the macula) progressively loses function, blurring or erasing the sharp, central vision used for reading, driving, and recognizing faces. Investors care because it creates sustained demand for drugs, medical devices, diagnostics, and care services—think of the macula as the camera’s center; if it fails, the market for treatments and related healthcare products can be large and long-lasting.

AI-generated analysis. Not financial advice.

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026.

KOLs leading the webcast include:

• Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine & Chairman, Ocugen Scientific Advisory Board
  
  
• Jay Chhablani, MD, Professor, University of Pittsburgh and UPMC Vision Institute, and President of NetraMind
  

Victor H. Gonzalez, MD, Retinal Surgeon, Valley Retina Institute, McAllen, Texas, Faculty at University of Texas Rio Grande Valley; and Syed M. Shah, MD, Vice Chair for Research and Digital Medicine, Director of Retina Service, Department of Ophthalmology at Emplfiy Health, La Crosse, WI, Ibn al-Haytham Professor, Department of Ophthalmology, Aga Khan University will join to answer questions.

Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 4629682
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available following the event on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com

FAQ

When is Ocugen (OCGN) presenting Phase 2 ArMaDa data for OCU410?

Ocugen will present on March 24, 2026 at 8:00 a.m. EDT. According to the company, the webcast will cover the full Phase 2 ArMaDa data set for OCU410 in geographic atrophy.

How can investors join the Ocugen (OCGN) March 24, 2026 webcast for OCU410 results?

Investors can join via live webcast on the Ocugen investor site or by phone using provided dial-in numbers. According to the company, a conference ID (4629682) is available for call access.

Who are the key opinion leaders speaking on Ocugen's OCU410 Phase 2 webcast?

Speakers include Lejla Vajzovic MD, Jay Chhablani MD, Victor H. Gonzalez MD, and Syed M. Shah MD. According to the company, these KOLs will join Ocugen leadership to discuss and answer questions.

Will Ocugen (OCGN) provide a replay of the March 24, 2026 OCU410 webcast?

Yes. A replay and archived webcast will be available after the event on the Ocugen investor site. According to the company, the recording will be posted following the live presentation and Q&A session.

What will the Ocugen (OCGN) webcast on March 24, 2026 focus on regarding OCU410?

The webcast will focus on the full Phase 2 ArMaDa clinical trial data for OCU410 in geographic atrophy (late-stage dry AMD). According to the company, presentations will include data review and a KOL-led Q&A with Ocugen executives.